Open Access

Uncovering the hidden risk: why lipoprotein(a) testing is crucial

Event: ESC Congress 2022
Topic: Cardiovascular Risk Assessment
Session type: Satellite Symposium
Sponsored by Novartis Pharma AG
Date: 27 August 2022
Time: 10:15 - 11:00

Congress Session

This content is currently on OPEN ACCESS

Sign in to view the resources

5 presentations in this session

Welcome and introduction.

Speaker: Professor J. Zamorano Gomez (Madrid, ES)
Thumbnail

Incorporating Lp(a) into risk classification for patients with ASCVD.

Speaker: Professor I. Hilgendorf (Freiburg, DE)
Thumbnail

Uncovering the risks: the value of early assessment in ASCVD - A clinical case.

Speaker: Professor J. Zamorano Gomez (Madrid, ES)
Thumbnail

Guidance on Lp(a) measurement: why, how, when?

Speaker: Doctor P. Kamstrup (Herlev, DK)
Thumbnail

4 speakers from this session

Professor Jose Luis Zamorano Gomez

University Hospital Ramon y Cajal de Madrid, Madrid (Spain)
41 presentations
3 followers

Professor Ingo Hilgendorf

University of Freiburg, Freiburg (Germany)
2 presentations
0 follower

Professor Jose Luis Zamorano Gomez

University Hospital Ramon y Cajal de Madrid, Madrid (Spain)
41 presentations
3 followers

Doctor Pia Kamstrup

Copenhagen University Hospital - Herlev Gentofte, Herlev (Denmark)
3 presentations
0 follower

This platform is supported by

logo Novo Nordisk